Literature DB >> 9287229

Stent placement compared with balloon angioplasty for obstructed coronary bypass grafts. Saphenous Vein De Novo Trial Investigators.

M P Savage1, J S Douglas, D L Fischman, C J Pepine, S B King, J A Werner, S R Bailey, P A Overlie, S H Fenton, J A Brinker, M B Leon, S Goldberg.   

Abstract

BACKGROUND: Treatment of stenosis in saphenous-vein grafts after coronary-artery bypass surgery is a difficult challenge. The purpose of this study was to compare the effects of stent placement with those of balloon angioplasty on clinical and angiographic outcomes in patients with obstructive disease of saphenous-vein grafts.
METHODS: A total of 220 patients with new lesions in aortocoronary-venous bypass grafts were randomly assigned to placement of Palmaz-Schatz stents or standard balloon angioplasty. Coronary angiography was performed during the index procedure and six months later.
RESULTS: As compared with the patients assigned to angioplasty, those assigned to stenting had a higher rate of procedural efficacy, defined as a reduction in stenosis to less than 50 percent of the vessel diameter without a major cardiac complication (92 percent vs. 69 percent, P<0.001), but they had more frequent hemorrhagic complications (17 percent vs. 5 percent, P<0.01). Patients in the stent group had a larger mean (+/-SD) increase in luminal diameter immediately after the procedure (1.92+/-0.30 mm, as compared with 1.21+/-0.37 mm in the angioplasty group; P<0.001) and a greater mean net gain in luminal diameter at six months (0.85+/-0.96 vs. 0.54+/-0.91 mm, P=0.002). Restenosis occurred in 37 percent of the patients in the stent group and in 46 percent of the patients in the angioplasty group (P=0.24). The outcome in terms of freedom from death, myocardial infarction, repeated bypass surgery, or revascularization of the target lesion was significantly better in the stent group (73 percent vs. 58 percent, P = 0.03).
CONCLUSIONS: As compared with balloon angioplasty, stenting of selected venous bypass-graft lesions resulted in superior procedural outcomes, a larger gain in luminal diameter, and a reduction in major cardiac events. However, there was no significant benefit in the rate of angiographic restenosis, which was the primary end point of the study.

Entities:  

Mesh:

Year:  1997        PMID: 9287229     DOI: 10.1056/NEJM199709113371103

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  42 in total

Review 1.  What is meant by intention to treat analysis? Survey of published randomised controlled trials.

Authors:  S Hollis; F Campbell
Journal:  BMJ       Date:  1999-09-11

Review 2.  Low molecular weight heparins in the cardiac catheterization laboratory.

Authors:  G Montalescot; M Cohen
Journal:  J Thromb Thrombolysis       Date:  1999-06       Impact factor: 2.300

Review 3.  Fortnightly review: Intracoronary stents.

Authors:  M M Gandhi; K D Dawkins
Journal:  BMJ       Date:  1999-03-06

Review 4.  Stent thrombosis: historical perspectives and current trends.

Authors:  D E Cutlip
Journal:  J Thromb Thrombolysis       Date:  2000-08       Impact factor: 2.300

5.  Real-world experience of drug-eluting stents in saphenous vein grafts compared to native coronary arteries: results from the prospective multicenter German DES.DE registry.

Authors:  Ibrahim Akin; Marcus Wiemer; Steffen Schneider; Jochen Senges; Matthias Hochadel; Gert Richardt; Mohamed Abdel-Wahab; Karl-Heinz Kuck; Christoph A Nienaber
Journal:  Clin Res Cardiol       Date:  2011-11-13       Impact factor: 5.460

Review 6.  Stenting of complex lesions: an overview.

Authors:  Usman Baber; Annapoorna S Kini; Samin K Sharma
Journal:  Nat Rev Cardiol       Date:  2010-09       Impact factor: 32.419

7.  Pathology of drug-eluting versus bare-metal stents in saphenous vein bypass graft lesions.

Authors:  Saami K Yazdani; Andrew Farb; Masataka Nakano; Marc Vorpahl; Elena Ladich; Aloke V Finn; Frank D Kolodgie; Renu Virmani
Journal:  JACC Cardiovasc Interv       Date:  2012-06       Impact factor: 11.195

8.  Comparison of the slow-release polymer-based paclitaxel-eluting Taxus-Express stent with the bare-metal Express stent for saphenous vein graft interventions.

Authors:  J Wöhrle; T Nusser; H A Kestler; M Kochs; V Hombach
Journal:  Clin Res Cardiol       Date:  2006-12-08       Impact factor: 5.460

9.  Implantation of paclitaxel-eluting stents in saphenous vein grafts: clinical and angiographic follow-up results from a multicentre study.

Authors:  Rainer Hoffmann; Tilmann Pohl; Ralf Köster; Ruediger Blindt; Peter Boeckstegers; Thomas Heitzer
Journal:  Heart       Date:  2006-08-29       Impact factor: 5.994

10.  Utility of drug-eluting stents in complex lesions and high-risk patients.

Authors:  Eugenia Nikolsky; Gregg W Stone
Journal:  Curr Treat Options Cardiovasc Med       Date:  2007-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.